AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nagata, K.
Right arrow Articles by Tamura, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nagata, K.
Right arrow Articles by Tamura, T.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2001, p. 1522-1527, Vol. 45, No. 5
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.5.1522-1527.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Inhibitory Activities of Lansoprazole against Respiration in Helicobacter pylori

Kumiko Nagata,1,* Nobuhito Sone,2 and Toshihide Tamura1

Department of Bacteriology, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501,1 and Department of Biological Engineering, Kyushu Institute of Technology, Iizuka, Fukuoka 820-8502,2 Japan

Received 4 December 2000/Returned for modification 8 January 2001/Accepted 19 February 2001

Lansoprazole and its derivative AG-1789 dose-dependently inhibited cellular respiration by an endogenous substrate and decreased the ATP level in Helicobacter pylori cells. The inhibitory action of lansoprazole and AG-1789 against respiration was specific to substrates such as pyruvate and alpha -ketoglutarate and similar to the inhibitory action of rotenone, which is an inhibitor for the mitochondrial respiratory chain. Growth inhibition by lansoprazole and AG-1789 as well as by rotenone was augmented at high oxygen concentrations under atmospheric conditions. Since the 50% inhibitory concentrations of these compounds for the respiration were close to their MICs for H. pylori growth, the growth inhibition might be due to respiratory inhibition by these compounds.

* Corresponding author. Mailing address: Department of Bacteriology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan. Phone: 0798 45 6548. Fax: 0798 40 9162. E-mail: kunagata{at}hyo-med.ac.jp.

Antimicrobial Agents and Chemotherapy, May 2001, p. 1522-1527, Vol. 45, No. 5
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.5.1522-1527.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2001 by the American Society for Microbiology. All rights reserved.